


SFW



PATENT--NO FEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:)	I hereby certify that this
)	paper is being deposited
TIMOTHY J. MARTINS ET AL.)	with the United States
)	Postal Service with suffi-
Serial No.: 10/758,675)	cient postage, as first
)	class mail, in an envelope
Filed: January 15, 2004)	addressed to:
)	Commissioner for Patents
For: CYCLIC AMP-SPECIFIC)	P.O. Box 1450
PHOSPHODIESTERASE INHIBITORS)	Alexandria, VA 22313-1450
)	
Attorney Docket No. 27866/39819)	Dated: May 24, 2004
)	
Group Art Unit: 1614)	
)	
Examiner: Unassigned)	
)	
)	
)	James J. Napoli
)	Registration No. 32,361
)	Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Pursuant to their duty of disclosure under 37 C.F.R. §1.56, applicants hereby bring to the examiner's attention patents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicants enclose a completed Form PTO-1449 listing the possibly pertinent patents and publications.

In accordance with 37 C.F.R. §1.98(d), copies of the patents and publications not enclosed herein were provided in a prior application that applicants

rely upon for an earlier filing date under 35 U.S.C. §120. Copies of nonenclosed documents listed in the attached Form PTO-1449 were provided to, or cited by, the examiner of the following patent applications:

Timothy J. Martins et al.
Serial No. 09/717,956
Filing Date: November 21, 2000
Title: Cyclic AMP-Specific
Phosphodiesterase Inhibitors
U.S. Patent No. 6,423,710; and

Timothy J. Martins et al.
Serial No. 10/151,202
Filing Date: May 17, 2002
Title: Cyclic AMP-Specific
Phosphodiesterase Inhibitors
U.S. Patent No. 6,716,871


This Information Disclosure Statement is submitted more than three months after the filing date of the above-identified application, and, to applicants' knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. §1.97(b), this Information Disclosure Statement shall be considered by the Patent Office.

The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

By

A handwritten signature in black ink, appearing to read "James J. Napoli", is written over a horizontal line.

James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
May 24, 2004



Form 1449PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/758,675		
		Filing Date	January 15, 2004		
		First Named Inventor	Timothy J. Martins		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet	1	of	2	Attorney Docket Number	27866/39819

U.S. PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY
		5,665,754	09/09/1997
		5,998,428	12/07/1999
		6,258,833	07/10/2001

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		J.E. Schultz et al., <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , 333, pp. 23-30 (1986).
		Z. Ma et al., <i>Tetrahedron: Asymmetry</i> , Vol. 8, No. 6, pp. 883-887 (1997).
		A. Robichaud et al., <i>Neuropharmacology</i> , 38, pp. 289-297 (1999).
		R.A. Allen et al., <i>Biochemical Pharmacology</i> , Vol. 57, pp. 1375-1382 (1999).
		J. Beavo et al., "Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action," Wiley and Sons, Chichester, pp. 3-14 (1990).
		T.J. Torphy et al., <i>Drug News and Perspectives</i> , 6, pp. 203-214 (1993).
		M.A. Giembycz et al., <i>Clin. Exp. Allergy</i> , 22, pp. 337-344 (1992).
		J. Semmler et al., <i>Int. J. Immunopharmacol.</i> , 15, pp. 409-413 (1993).
		K.L. Molnar-Kimber et al., <i>Mediators of Inflammation</i> , 1, pp. 411-417 (1992).
		M.W. Verghese et al., <i>J. Mol. Cell. Cardiol.</i> , 21 (Suppl. 2), S61 (1989).
		C.P. Nielson et al., <i>J. Allergy Immunol.</i> , 86, pp. 801-808 (1990).
		P.T. Peachell et al., <i>J. Immunol.</i> , 148, pp. 2503-2510 (1992).
		G. Dent et al., <i>J. Pharmacol.</i> , 103, pp. 1339-1346 (1991).
		S.A. Robicsek et al., <i>Biochem. Pharmacol.</i> , 42, pp. 869-877 (1991).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/758,675
				Filing Date	January 15, 2004
				First Named Inventor	Timothy J. Martins
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	27866/39819

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		H.S. Dhillon et al., <i>J. Neurotrauma</i> , 12, pp. 1035-1043 (1995).
		N. Suttorp et al., <i>J. Clin. Invest.</i> , 91, pp. 1421-1428 (1993).
		M.R. Bristow et al., <i>Circulation</i> , 97, pp. 1340-1341 (1998).
		G. Poli et al., <i>Proc. Natl. Acad. Sci. USA</i> , 87, pp. 782-785 (1990).
		P. Orosz et al., <i>J. Exp. Med.</i> , 177, pp. 1391-1398 (1993).
		M. Mentz et al., <i>Blood</i> , 88, pp. 2172-2182 (1996).
		S. Takeda et al., <i>Kidney Int.</i> , 37, p. 362 (1990).
		D. Chabardea et al., <i>Kidney Int.</i> , 35, p. 494 (1989).
		C.D. Nicholson, <i>Psychopharmacology</i> , 101, p. 147 (1990).
		F. Eckmann et al., <i>Curr. Ther. Res.</i> , 43, p. 291 (1988).
		A. Klodzinska et al., <i>Neuropharmacology</i> , 38, p. 1831 (1991).
		H. Kato et al., <i>Eur. J. Pharmacol.</i> , 272, p. 107 (1995).
		G. Gardos et al., <i>J. Clin. Pharmacol.</i> , 16, p. 304 (1976).
		I. Shoulson et al., <i>Neurology</i> , 25, p. 722 (1975).
		T. Hayakawa et al., <i>Clin. Exp. Pharmacol. Physiol.</i> , 26, p. 421 (1999).
		R.D. Porsolt et al., <i>Eur. J. Pharmacol.</i> , 47, p. 379 (1978).
		R.D. Porsolt et al., <i>Eur. J. Pharmacol.</i> , 57, p. 431 (1979).
		L. Steru, <i>Psychopharmacology</i> , 85, p. 376 (1985).
		M. Takahashi, <i>J. Neuroscience</i> , 19, p. 610 (1999).
		D. Pinsky et al., <i>J. Clin. Invest.</i> , 92, pp. 2994-3002 (1993).
		<i>Antidepressants: neurochemical, behavioral and clinical perspectives</i> , Enna, Malick, and Richelson, eds., Raven Press, pp. 121-139 (1981).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.